12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CV-301: Preliminary Phase II data

Last year, Bavarian Nordic received exclusive, worldwide rights to the vaccine to treat certain cancers from the NCI, which regained rights to CV-301 after the previous licensee, Therion Biologics Corp., declared bankruptcy in 2006 (see BioCentury, Oct. 10, 2011). Sanofi (Euronext:SAN; NYSE:SNY, Paris, France) markets ...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >